Cabozantinib Discontinuation Before Surgery
Stop cabozantinib at least 3 weeks (21 days) before any scheduled surgery, including dental procedures. This is the explicit FDA-approved recommendation for perioperative management 1.
Key Recommendation
The FDA drug label for cabozantinib (CABOMETYX) provides clear, unambiguous guidance that supersedes general perioperative guidelines for other drug classes. The 3-week preoperative discontinuation period is mandatory regardless of surgery type 1.
Rationale and Mechanism
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that blocks VEGF receptors and other angiogenic pathways critical for wound healing. The 3-week washout period accounts for:
- Drug elimination half-life considerations - allowing adequate clearance of active drug
- Reversal of anti-angiogenic effects - restoring normal wound healing capacity
- Reduction of bleeding risk - minimizing perioperative hemorrhagic complications
- Prevention of wound dehiscence - avoiding impaired tissue repair
Anti-angiogenic therapies like cabozantinib significantly impair physiological wound healing, with parietal complications reported in 5-50% of cases when perioperative management is inadequate 2.
Clinical Application
Preoperative Management
- Discontinue cabozantinib exactly 3 weeks before surgery - no exceptions for minor procedures
- This applies to all surgical interventions, including dental surgery 1
- Do not attempt shorter discontinuation periods even for "low-risk" procedures
Postoperative Resumption
While the FDA label emphasizes preoperative discontinuation, general principles for TKI resumption suggest:
- Resume 3-4 weeks after surgery once adequate wound healing is confirmed 2
- Ensure hemostasis is adequate before restarting
- Monitor wound healing closely
Important Caveats
This 3-week rule is specific to cabozantinib and should not be confused with other perioperative medication management guidelines. The provided evidence includes extensive guidance on antiplatelet agents, anticoagulants, and other immunosuppressive medications 3, 4, 3, but these do NOT apply to cabozantinib.
The half-life-based approaches used for other TKIs (24-48 hours preoperatively) 2 are inadequate for cabozantinib - the FDA mandates the longer 3-week period based on its specific pharmacologic profile and wound healing effects.
Do not substitute cabozantinib capsules for CABOMETYX tablets - they are not bioequivalent 1.